AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

February 1, 2019

DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Retinoic Acid Receptors (RARs) Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Provides a snapshot of the therapeutics pipeline activity for Retinoic Acid Receptors (RARs) Agonist Features the Retinoic Acid Receptors (RARs) Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Retinoic Acid Receptors (RARs) Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Retinoic Acid Receptors (RARs) Agonist

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Retinoic Acid Receptors (RARs) Agonist to formulate effective R&D strategies Assess challenges and opportunities that influence Retinoic Acid Receptors (RARs) Agonist research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Retinoic Acid Receptors (RARs) Agonist Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Retinoic Acid Receptors (RARs) Agonist to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Topics Covered

1. Report Introduction

2. Retinoic Acid Receptors (RARs) Agonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Retinoic Acid Receptors (RARs) Agonist

4. Comparative Analysis

5. Retinoic Acid Receptors (RARs) Agonist Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Retinoic Acid Receptors (RARs) Agonist Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Featured

Shionogi Syros Pharmaceuticals TMRC Co. Ltd. Allergan Galderma Clementia Pharmaceuticals Roche

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4jj2vp/retinoic_acid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005250/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/01/2019 07:54 AM/DISC: 02/01/2019 07:54 AM

http://www.businesswire.com/news/home/20190201005250/en